Please login to the form below

Not currently logged in
Email:
Password:

Europe delays EMA relocation decision

Will resolve the issue in November, one month later than expected

EMAThe decision on which country will host Europe’s pharma regulator once the UK leaves the European Union has been postponed by one month.

Currently based in London, the European Medicines Agency (EMA) is now expected to learn later this year in November where it will be moved to.

The decision will be taken at a meeting of the heads of state or government from the 27 states that will make up the EU after March 29, 2019, and its delay has prompted pharma to voice its concern.

European trade body EFPIA acknowledged the complexity of the Brexit negotiations, but argued in a statement “medicines constitute a special case in term of securing swift agreement on both sides”.

“It is imperative for the safeguarding of public health that we ensure future alignment between the UK and EU regulatory regimes in order to maintain capacity, processes and timeframes for the introduction of new medicines for patients,” it added.

Echoing this Dr Virginia Acha, executive director of research, medicine and innovation at the UK’s ABPI, said: “It will be critical to avoid divergence and duplication of regulatory regimes, so that patient safety is not put at risk."

The EU’s November meeting will also see the post-Brexit location decided of the European Banking Authority (EBA), which must leave London too.

EU member states can bid to host both, but - with the EMA’s fate to be decided first - the country that wins the right to the medicines regulator cannot then continue with its bid for the EBA.

Countries that have so far thrown their hats into the ring for the EMA contest include Copenhagen, Barcelona, Lisbon and Dublin - any more that are interested have until July 31 to submit their offer.

Article by
Dominic Tyer

26th June 2017

From: Regulatory

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...
Leveraging Real-World Evidence for Cell and Gene Therapies
Regulators and reimbursement bodies are increasingly turning to real-world evidence (RWE) to understand the long-term value of drugs, in particular novel therapies. Here, Mariam Bibi, Senior Director, Global RWE at...
Food Allergy – Is avoidance the only option?
Following on from Allergy Awareness Week 2022, we’re continuing the discussion about food allergies and the experiences of those who live with them. In this blog, we discuss the current...